3 penny stocks are poised for big gains

Known for their unusually high risk/reward profile, Penny stocks All too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dumps and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence.

All of this is to say that investors should be wary of anyone Penny stocksEspecially one that seems too good to be true, because it could be part of a A multi-million dollar scam. On the other hand, investors who are comfortable taking a high level of risk and are willing to thoroughly research potential investment targets can find great deals.

While there’s no guarantee that a penny stock investment will pay off, below are three companies trading for less than $5 per share that stand out from the crowd.

Wuzix: Major new contract, retail product launch

Wuzix Corporation NASDAQ: VUZI Design and manufacture Smart glasses and related augmented reality products. While many people think of these products as being designed for everyday consumers, Vuzix focuses specifically on applications in the defense and medical spaces.

At the end of November 2024, Vuzicks announced a major contract along with an unnamed US aerospace and defense company to supply customized waveguides for use in heads-up displays. That same week, the company reported the general availability of its Z100 smart glasses for the everyday wearable market and Q3 2024 earnings results. In the latest quarter, the company successfully reduced its quarterly cash operating expenses by 28% as it also received a subsidiary equity investment of $10 million, with an additional $10 million to come. Together, these factors help sustain operations as Vuzix continues to scale its products and win more contracts.

Given this November-to-November surge of positive news, it is not surprising that Vuzix posted returns of nearly 88% for the five days to November 26, 2024, compared to the 52-week high achieved in December 2023. Corresponds to the highest level.

Geowax Labs: Trial Results, Broad Pipeline Promise

Geowax Labs Inc. NASDAQ: GOVX There is one Clinical-stage biotech A firm working to develop vaccines to treat Covid-19, HIV, and other infectious diseases, as well as some solid tumor cancers. Many small biotech companies without a strong line of commercially available products attract the attention of investors when they report promising trial data, and GeoVax is no exception.

In GeoVax’s case, investors noted that its GEO-CM04S1, a dual-antigen Covid vaccine candidate, showed positive Phase 2 trial results in chronic lymphocytic leukemia (CLL), a common form of leukemia in adults. is In addition, the company also has a vaccine candidate against ampox and smallpox in its pipeline. It was also recently the recipient of a BARDA Project NextGen Award worth nearly $400 million to support a pivotal comparative trial.

Given strong potential across several products in development, GeoVax has earned a buy rating from seven Wall Street analysts, who have also assigned it a consensus price target of $14.20, a 400% upside to current price levels. .

Cardiol therapeutics: a late-stage trial for a potential treatment

Cardiol Therapeutics Inc. NASDAQ: CRDL Another emerging biotech with promising products in development. In this case, one drug candidate to keep an eye on is CardiolRx, which showed strong results in a phase 2 study for the treatment of recurrent pericarditis. The company is preparing for late-stage clinical trials, an important step before developing the drug for the market.

Cardiol was also Recently added in PRISM Marketview’s Emerging Biotech Index, which further strengthens the company’s profile. CRDL was up nearly 72% in the year ended November 26, 2024, although it has lost nearly half its value since June.

Stability is the key

For the penny stocks above—and any other companies without a steady, established stream of revenue—continuing funding, keeping costs to a minimum, and developing a path to profitability are key. Before investing in any penny stock, investors should carefully research a potential target firm for signs that it is making progress in each of these areas.

Before considering Cardiol Therapeutics, you may want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified Five stocks That top analysts are quietly telling their clients to buy before the broader market arrives… and Cardiol Therapeutics was not on the list.

While Cardiol Therapeutics currently has a “buy” rating among analysts, top analysts believe these five stocks are better buys.

Check out five stocks here

Like this article? Share it with a friend.

Link copied to clipboard.